Prognostic Factors for Metastatic Kidney Cancer

Drucker, Beverly J.; Mazumdar, Madhu; Motzer, Robert J.

doi:10.1007/978-1-4615-0451-1_8

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the general belief that metastatic pRCC has a more aggressive profile than metastatic cRCC, few centers have evaluated prognostic significance of histology in patients undergoing cytoreductive nephrectomy, and none of the prognostic models developed for patients with metastatic RCC have integrated histologic subtype as a separate prognostic variable 14–18. Although no comparison to the matched cRCC patient cohort was reported, investigators from the Memorial Sloan‐Kettering Cancer Center reported a median survival of only 8 months in 38 metastatic pRCC patients treated at their center 15.…”

Section: Discussionmentioning

confidence: 99%

Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma

Margulis

Tamboli

Matin

et al. 2008

Cancer

View full text Add to dashboard Cite

RNA interference (RNAi) has been recently applied to improve the yield and quality of recombinant proteins produced in Chinese hamster ovary (CHO) cells, the most commonly used mammalian cell line for production of complex biopharmaceuticals. Proteomic profiling of CHO cells undergoing gene amplification identified cofilin, a key regulatory protein of actin cytoskeletal dynamics, as a cellular target for genetic engineering studies. Transient reduction of cofilin by small interfering RNA (siRNA) enhanced specific productivity in recombinant CHO cells by up to 80%. CHO cell lines expressing cofilin‐specific short hairpin RNA (shRNA) vectors showed up to a 65% increase in specific productivity. These results suggest that modulation of cofilin, and its regulatory pathways, may be a new approach to enhance recombinant protein productivity in CHO cells. Biotechnol. Bioeng. 2012; 109:528–535. © 2011 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma

Margulis

Tamboli

Matin

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…In addition, many patients having initially resectable RCC eventually recur. For these reasons, the overall prognosis of RCC is not satisfactory with the overall five‐year survival being as low as 5%‐15% . RCC is a highly vascularized tumor involving hypoxia inducible factor (HIF)/vascular endothelial growth factor (VEGF) and other proangiogenic factors.…”

Section: Introductionmentioning

confidence: 99%

Everolimus suppresses invasion and migration of renal cell carcinoma by inhibiting FAK activity and reversing epithelial to mesenchymal transition in vitro and in vivo

Chen

et al. 2017

Environmental Toxicology

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults and the major cause of mortality in urological cancer. Most patients with RCC are asymptomatic until the disease is advanced and unresectable. In this situation, systemic therapy with immunotherapy or molecularly targeted therapy agents play an important role in therapeutic strategy. Everolimus (EVE), an m-TOR inhibitor, has the potential to inhibit tumor progression at multiple levels and is indicated for the treatment of advanced RCC in patients whose disease has metastasis. In this study, we provide molecular evidence associated with the antimetastatic effect of everolimus by demonstrating the suppression of lung metastasis of 786-O cells in mouse model. This effect was associated with reduced protein expressions of p-FAK (Tyr 925), p-Src (Tyr416), Vimentin, and RhoA and also with increased the E-cadherin protein expression. In summary, these findings provide new insights into the molecular mechanisms involved in the antimetastatic effect of everolimus and are thus valuable in the treatment of metastatic RCC.

show abstract

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

et al. 2009

View full text Add to dashboard Cite

Background: Sorafenib and sunitinib are tyrosine kinase inhibitors with largely overlapping specificities, approved for the treatment of metastatic renal-cell carcinoma (RCC). It was unclear whether the similarities of the two drugs would lead to complete cross-resistance, or whether sequential application would be efficacious. Methods: Patients with metastatic RCC and progression on sorafenib treatment were treated with repeated cycles of sunitinib, 50 mg for 4 weeks, followed by a 2-week break. Response (Response Evaluation Criteria in Solid Tumors, RECIST) was assessed every second cycle. Results: A total of 22 patients with progression on sorafenib were accrued. Initially, sorafenib treatment was efficacious in all patients, with 7 showing partial response (PR) and 15 stable disease (SD), and subsequent disease progression. With 4 PRs (18%) and 12 SD (55%) a disease control rate of 73% was achieved. The median progression-free survival (PFS) on sunitinib was 21.5 weeks; median overall survival (OS) was not reached. Estimated 1-year PFS and OS were 31 and 60%, respectively. There was no apparent relationship between response to sorafenib and outcome on sunitinib. Conclusion: In our cohort of patients with RCC and progression after initial efficacy of sorafenib, the efficacy data of second-line sunitinib were close to published results of first-line treatment, suggesting limited clinically relevant cross-resistance.

show abstract

Prognostic Factors for Metastatic Kidney Cancer

Cited by 3 publications

References 26 publications

Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma

Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma

Everolimus suppresses invasion and migration of renal cell carcinoma by inhibiting FAK activity and reversing epithelial to mesenchymal transition in vitro and in vivo

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

Contact Info

Product

Resources

About